CG Oncology (CGON) Jefferies Global Healthcare Conference 2026 summary

Company focus and product positioning

• Focused on developing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC), targeting up to 150,000 patients in the U.S.

• Cretostimogene uniquely combines direct tumor oncolysis with an anti-tumor immune response, differentiating it from other approved therapies.

• Zero Grade 3 adverse events reported, with a favorable safety profile compared to competitors.

• Product aims to prevent radical cystectomy and progression to muscle-invasive or metastatic disease.

Clinical data and competitive differentiation

• Achieved a 76% complete response (CR) rate in BCG-unresponsive CIS cohort; median duration of response exceeds 25 months.

• At 12 and 24 months, CR rates are 46% and 42% respectively, with 90% of 12-month responders maintaining CR at 24 months.

• Competitor data, such as J&J's TAR-200, lacks durability beyond 12 months and shows higher toxicity.

• Upcoming data readouts expected later in the year, including extended durability and combination studies.

Market opportunity and patient population

• BCG-unresponsive high-risk NMIBC population estimated at 25,000, modeled as a blend of incidence and prevalence.

• Prevalence-based modeling recommended due to high recurrence and progression rates.

• Broader U.S. bladder cancer prevalence is about 700,000, with high recurrence rates over multiple years.